Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia
Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2717-2743
DOI: 10.1021/acs.jmedchem.2c01665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.02.2023. Verfasst von Atsunori Kaneshige und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: STAT5 Transcription Factor, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, University of Michigan.
Abstract (Originalsprache)
STAT5 is an attractive therapeutic target for human cancers. We report herein the discovery of a potent and selective STAT5 degrader with strong antitumor activity in vivo. We first obtained small-molecule ligands with sub-micromolar to low micromolar binding affinities to STAT5 and STAT6 SH2 domains and determined co-crystal structures of three such ligands in complex with STAT5A. We successfully transformed these ligands into potent and selective STAT5 degraders using the PROTAC technology with AK-2292 as the best compound. AK-2292 effectively induces degradation of STAT5A, STAT5B, and phosphorylated STAT5 proteins in a concentration- and time-dependent manner in acute myeloid leukemia (AML) cell lines and demonstrates excellent degradation selectivity for STAT5 over all other STAT members. It exerts potent and specific cell growth inhibitory activity in AML cell lines with high levels of phosphorylated STAT5. AK-2292 effectively reduces STAT5 protein in vivo and achieves strong antitumor activity in mice at well-tolerated dose schedules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Life Science Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Duxin Sun, Shaomeng Wang
Förderung
- NCI NIH HHS
- National Cancer Institute
- University of Michigan
- Roivant Sciences
- Proteovant Therapeutics
- Oncopia Therapeutics
Zitieren
APA
Kaneshige, A., Bai, L., Wang, M., McEachern, D., Meagher, J. L., Xu, R., Kirchhoff, P. D., Wen, B., Sun, D., Stuckey, J. A., & Wang, S. (2023). Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 66(4), 2717-2743. https://doi.org/10.1021/acs.jmedchem.2c01665
Vancouver
Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, et al. Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2023;66(4):2717-2743. doi:10.1021/acs.jmedchem.2c01665
BibTeX
@article{Kaneshige2023,
author = {Kaneshige, Atsunori and Bai, Longchuan and Wang, Mi and McEachern, Donna and Meagher, Jennifer L and Xu, Renqi and Kirchhoff, Paul D and Wen, Bo and Sun, Duxin and Stuckey, Jeanne A and Wang, Shaomeng},
title = {Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {4},
pages = {2717--2743},
doi = {10.1021/acs.jmedchem.2c01665}
}
EUVIMED